Physician

Frank John Lichtenberger, MD, PHD

According to 2025 Medicare claims, Frank Lichtenberger, MD, PHD (NPI: 1750590097) practices allergy/immunology in the Charlotte-Concord-Gastonia, NC-SC market, with the plurality of this provider's patient population coming from Iredell, NC. This provider's primary affiliated billing organization is NC IMMUNOLOGY, PC (NPI: 1619785920; TIN: 332466558) and primary practice location at 28677-3517. Lichtenberger is affiliated with the agilon health Coastal ACO, Inc. (ACO ID: D0107), participating under the REACH model.

Lichtenberger's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 317 traditional Medicare patients, billed 35,140 HCPCS/CPT codes, and received $1,146,987 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,537 prescription claims across 279 beneficiaries totaling $7,106,418 in drug costs, led by Berinert (C1 Esterase Inhibitor). DME data shows 802 claims. Open Payments data shows 62 records totaling $33,844. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $239,992 to $1,146,987. Similarly, Part D prescription costs have moved sharply higher in recent years, from $115,840 to $7,106,418. In contrast, DME billing represents a smaller volume and moved from a lower plateau to a higher plateau, from $3,236 to $15,321.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	421	16,568	$239,992
2016	350	17,736	$271,340
2017	304	13,512	$210,380
2018	357	15,182	$244,159
2019	361	16,700	$292,265
2020	341	15,162	$273,984
2021	494	18,433	$419,402
2022	374	22,736	$521,314
2023	301	33,794	$859,974
2024	317	35,140	$1,146,987

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	219	972	$115,840
2016	234	1,170	$453,578
2017	231	1,311	$778,998
2018	273	1,376	$915,795
2019	308	1,616	$1,377,173
2020	273	1,610	$1,619,885
2021	297	1,693	$1,649,743
2022	295	1,612	$4,784,011
2023	279	1,482	$6,752,857
2024	279	1,537	$7,106,418

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	159	$14,303
2016	N/R	88	$11,106
2017	N/R	123	$60,500
2018	N/R	307	$356,959
2019	15	712	$978,848
2020	52	982	$1,469,957
2021	39	1,080	$1,754,356
2022	56	1,083	$1,695,873
2023	40	1,145	$1,832,812
2024	31	802	$1,429,774

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	116	185	$84
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	88	97	$63
95165	Professional service for preparation and provision of 1 or more antigens	124	4,141	$10
95117	Professional service for multiple injections of allergen	112	1,277	$8
82784	Gammaglobulin (immune system protein) measurement	83	303	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Berinert	C1 Esterase Inhibitor	13	374	$3,098,193
Ruconest	C1 Esterase Inhibitor, Recomb	11	234	$1,370,130
Takhzyro	Lanadelumab-Flyo	25	700	$1,142,116
Gammagard Liquid	Immun Glob G(Igg)/Gly/Iga Ov50	37	924	$241,077
Xolair	Omalizumab	54	1,512	$217,736

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1576	Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	57	$285,462
J1558	Injection, immune globulin (xembify), 100 mg	N	N/R	55	$268,980
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	67	$256,637
J1575	Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin	N	N/R	45	$209,610
J1555	Injection, immune globulin (cuvitru), 100 mg	N	N/R	41	$191,994

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	61	$33,844	BioCryst US Sales Co., LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	1	$23,683	Consortium of Independent Immunology Clinics, LLC

Explore More Providers

FAQ

What Medicare data is available for Frank John Lichtenberger, MD, PHD?

Tedicare shows public-source Medicare data for Frank John Lichtenberger, MD, PHD (NPI 1750590097), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Frank John Lichtenberger, MD, PHD have ACO affiliation data?

Frank John Lichtenberger, MD, PHD is shown with ACO affiliation data for agilon health Coastal ACO, Inc. (REACH, ACO ID D0107).

What billing organization is linked to Frank John Lichtenberger, MD, PHD?

Frank John Lichtenberger, MD, PHD is linked to NC IMMUNOLOGY, PC (billing NPI 1619785920) in the available physician profile data.

Does Frank John Lichtenberger, MD, PHD have Open Payments data?

Frank John Lichtenberger, MD, PHD has 62 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.